AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.530

+0.0306.00%

Volume:1.19M

Turnover:615.65K

Market Cap:318.21M

PE:-22.41

High:0.535

Open:0.505

Low:0.500

Close:0.500

52wk High:0.785

52wk Low:0.340

Shares:600.40M

Float Shares:467.70M

Volume Ratio:1.35

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.024

EPS(LYR):-0.024

ROE:-83.97%

ROA:-32.13%

PB:23.78

PE(LYR):-22.41

Loading ...

Overview Company News Filings

Dimerix's Cash Outflow to Materially Reduce in Current Quarter, Euroz Hartleys Says

MT Newswires Live

BRIEF-Dimerix Appoints Mike Tonroe As CFO

Dimerix Appoints CFO

MT Newswires Live

Dimerix Ltd-Appointment of CFO/Company Secretary

THOMSON REUTERS

Dimerix's Drug Candidate Approval by FDA Unrelated to US Peer's New Drug Application Approval Date

MT Newswires Live

Dimerix Ltd-Clinical Trial Update at J.p. Morgan Healthcare Conference

THOMSON REUTERS

Dimerix Set to Receive 'Substantial' Milestone Payments, Euroz Hartleys Says

MT Newswires Live

Dimerix Says US FDA Confirms Primary Endpoint Supports Approval of Drug Candidate in Kidney Disease Trial

MT Newswires Live

BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale

Dimerix Agrees to Acquire US Licensing Partner for Nearly $5 Billion

MT Newswires Live

Dimerix Ltd-Biomarin to Acquire Dimerix US Partner, Amicus Therapeutics

THOMSON REUTERS

Dmx-200 Action3 Phase 3 Trial Completes Recruitment

THOMSON REUTERS

Dimerix Completes Dosing of 286 Adult Patients in Phase Three Kidney Disease Drug Candidate Trial

MT Newswires Live

ASX Penny Stocks To Consider In December 2025

Simply Wall St.

Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial

MT Newswires Live

Dimerix Ltd-Successful Completion of Planned Idmc Review

THOMSON REUTERS

Dimerix's Potential Interim Results May Potentially Enable Accelerated Approval in the US in 2026, Euroz Hartleys Says

MT Newswires Live

Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys

MT Newswires Live

3 hot sectors, a handful of stock ideas, and what could come next

Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.53,"timestamp":1770700320000,"preClose":0.5,"halted":0,"volume":1191876,"delay":0,"changeRate":0.06000000000000005,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.023645,"marketStatus":"Closed","change":0.03,"latestTime":"02-10 16:12:00 AEDT","open":0.505,"high":0.535,"low":0.5,"amount":615650,"amplitude":0.07,"askPrice":0.54,"askSize":16095,"bidPrice":0.52,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.023645,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.5,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.350843,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-32.13%","roe":"-83.97%","lyrEps":-0.023645,"volumeRatio":1.350843,"shares":600396776,"dividePrice":0,"high":0.535,"amplitude":0.07,"preClose":0.5,"low":0.5,"week52Low":0.34,"pbRate":"23.78","psRate":"56.96","week52High":0.785,"institutionHeld":0,"latestPrice":0.53,"committee":0.108187,"eps":-0.023645,"divideRate":0,"volume":1191876,"delay":0,"ttmEps":-0.023645,"open":0.505,"prevYearClose":0.55,"prevWeekClose":0.49,"prevMonthClose":0.505,"prevQuarterClose":0.55,"fiveDayClose":0.515,"twentyDayClose":0.545,"sixtyDayClose":0.495,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608653838","title":"Dimerix's Cash Outflow to Materially Reduce in Current Quarter, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2608653838","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608653838?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:18","pubTimestamp":1769995131,"startTime":"0","endTime":"0","summary":"Dimerix's  cash outflows are expected to materially reduce in the current quarter as recruitment, the company's largest component of clinical trial expenditure, has been completed, according to a Jan. 30 report by Euroz Harlteys.The company earlier said it had reached its full recruitment target, enrolling a total of 309 patients, and recorded cash outflows of AU$11.1 million in the December 2025 quarter.Upon receipt of approval from the US Food and Drug Administration , the company can proceed with an interim analysis of drug candidate DMX-200 in the ACTION3 trial for patients with focal segmental glomerulosclerosis, in the subsequent weeks, Euroz said.This may support the accelerated approval application and potential US commercialization of DMX-200 in the second half of the year, Euroz noted.If the US FDA does not approve the analysis, Dimerix would be required to complete a study of the drug, delaying both approval and the commercialization by about two years, Euroz added.Euroz mai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2605125721","title":"BRIEF-Dimerix Appoints Mike Tonroe As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605125721","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605125721?lang=en_us&edition=fundamental","pubTime":"2026-01-21 09:37","pubTimestamp":1768959451,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Appoints Mike Tonroe As CFOJan 21 (Reuters) - Dimerix Ltd DXB.AX:APPOINTMENT OF CFO/COMPANY SECRETARYAPPOINTS MIKE TONROE AS CFOFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUE8GHV2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2605114264","title":"Dimerix Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605114264","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605114264?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:24","pubTimestamp":1768947849,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) appointed Mike Tonroe as chief financial officer, effective Jan. 29, according to a Wednesday filing with the Australian bourse.Tonroe brings over 30 years of experience, having most recently served as the CFO of Imugene (ASX:IMU), the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","IMU.AU","DXB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2605415141","title":"Dimerix Ltd-Appointment of CFO/Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2605415141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605415141?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:28","pubTimestamp":1768944510,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUE8GHV2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2603662805","title":"Dimerix's Drug Candidate Approval by FDA Unrelated to US Peer's New Drug Application Approval Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2603662805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603662805?lang=en_us&edition=fundamental","pubTime":"2026-01-14 14:38","pubTimestamp":1768372704,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration  approval of Dimerix's  drug candidate DMX-200 is not to be impacted by the FDA's extension of the approval decision date for US-listed Travere Therapeutics' supplemental New Drug Application, according to a Wednesday note by Euroz Hartleys.The decision is unrelated to the FDA's prior feedback to the company that supports approval of DMX-200, in the ACTION3 trial for patients with Focal Segmental Glomerulosclerosis, Euroz said.In December 2025, the FDA requested further information and documentation, which the company said it expected to provide shortly.Euroz continues to believe that the FDA approval for Travere's application will have an outcome that ranges from neutral to positive for the company.It maintained its speculative buy rating on the company and its AU$1.68 price target.Shares of the company rose 3% at market close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2602568674","title":"Dimerix Ltd-Clinical Trial Update at J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602568674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602568674?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:28","pubTimestamp":1768166906,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUE3KLG90:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2595201964","title":"Dimerix Set to Receive 'Substantial' Milestone Payments, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2595201964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595201964?lang=en_us&edition=fundamental","pubTime":"2025-12-29 13:32","pubTimestamp":1766986360,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) is poised to receive \"substantial\" milestone payments after completing the interim analysis to support the US Food and Drug Administration's (FDA) potential accelerated approval appl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2593827449","title":"Dimerix Says US FDA Confirms Primary Endpoint Supports Approval of Drug Candidate in Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593827449","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593827449?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:15","pubTimestamp":1766531713,"startTime":"0","endTime":"0","summary":"Dimerix  said the US Food and Drug Administration  confirmed the proposed primary endpoint of percent reduction in proteinuria compared to placebo, which supports approval of drug candidate DMX-200, in the ACTION3 trial for patients with Focal Segmental Glomerulosclerosis, a type of kidney disease, according to a Wednesday filing with the Australian bourse.The US FDA has requested further information and documentation, which the company expects to provide shortly, the filing said.The company expects the blinded analysis for the trial to occur in early 2026, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2593031731","title":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2593031731","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593031731?lang=en_us&edition=fundamental","pubTime":"2025-12-22 12:10","pubTimestamp":1766376612,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale** Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months** Stock touches its biggest intraday pct gain in six months, if gains hold** Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion** Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases** Stock up 80.89% YTD, including session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL6N3XS07Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","FOLD","IE00B19Z3581.USD","LU2065170008.USD","IE00B7SZLL34.SGD","LU2065169927.USD","IE00B19Z3B42.SGD","IE0002270589.USD","DXB.AU","BK4566","BK7501","LU2065171402.SGD","BK4139","BMRN","LU2065171311.SGD","BK7067"],"gpt_icon":0},{"id":"2593176949","title":"Dimerix Agrees to Acquire US Licensing Partner for Nearly $5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176949","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593176949?lang=en_us&edition=fundamental","pubTime":"2025-12-22 07:05","pubTimestamp":1766358347,"startTime":"0","endTime":"0","summary":"Dimerix  agreed to acquire its US commercial licensing partner, Amicus Therapeutics, for about $4.8 billion in cash, according to a Friday filing with the Australian bourse.The deal includes the company's commercial licensing contract, under which the company is eligible to receive $590 million in payments, the filing said.The company's license deals outside the US remain unaffected, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2593175233","title":"Dimerix Ltd-Biomarin to Acquire Dimerix US Partner, Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593175233?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:16","pubTimestamp":1766355415,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nTUEBNHV0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2591182326","title":"Dmx-200 Action3 Phase 3 Trial Completes Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2591182326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591182326?lang=en_us&edition=fundamental","pubTime":"2025-12-15 15:00","pubTimestamp":1765782000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA3KLRWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2591969743","title":"Dimerix Completes Dosing of 286 Adult Patients in Phase Three Kidney Disease Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591969743","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591969743?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:38","pubTimestamp":1765777087,"startTime":"0","endTime":"0","summary":"Dimerix  said that the ACTION3 phase three trial of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis completed the recruitment and dosing of 286 adult patients, according to a Monday Australian bourse filing.The trial is exploring the efficacy and safety of DMX-200 in focal segmental glomerulosclerosis patients when dosed in combination with standard-of-care angiotensin II receptor blocker over two years. It is designed to show evidence of proteinuria reduction and kidney function during the trial, aimed at generating sufficient evidence to support marketing approval.The trial opened 219 sites for recruitment across 21 countries, including the US, Europe, the UK, Japan, China, Hong Kong, Taiwan, Malaysia, Australia, and New Zealand.Of the 286 adult patients dosed in the trial, 69 completed the full two-year treatment period, and of those, 65 entered voluntarily into the open-label extension study, representing a 94% uptake.Dimerix and its US partner, Amicu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2590422573","title":"ASX Penny Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590422573","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590422573?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:05","pubTimestamp":1765505127,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or newer companies, continue to attract attention for their potential growth and value propositions. Despite being considered an outdated term by some, these stocks remain relevant as they can offer unique opportunities for those looking to explore under-the-radar investments with strong financial...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SSM.AU","WAF.AU","BK7096","BK7132","BK7012","DXB.AU","BK7501","NUZ.AU","AAL.AU","BK7507","BK7048","BK7055","BK7045","DSK.AU","BK7077","MTO.AU","EDU.AU","BK7067","BK7508","IGL.AU","MLX.AU","VRS.AU","BK7050","BK7104","BK7095","GWA.AU","BK7143","BK7128","EZZ.AU","BK7506","BK7111"],"gpt_icon":0},{"id":"2584999337","title":"Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999337","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584999337?lang=en_us&edition=fundamental","pubTime":"2025-11-19 11:09","pubTimestamp":1763521785,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2584969973","title":"Dimerix Ltd-Successful Completion of Planned Idmc Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969973?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:05","pubTimestamp":1763503547,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUEMLLG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2582353818","title":"Dimerix's Potential Interim Results May Potentially Enable Accelerated Approval in the US in 2026, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2582353818","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582353818?lang=en_us&edition=fundamental","pubTime":"2025-11-11 15:19","pubTimestamp":1762845598,"startTime":"0","endTime":"0","summary":"Dimerix  is approaching key catalysts, including potential interim results, which could potentially enable a faster approval in the US in 2026 and first sales immediately thereafter, according to a Sunday note by Euroz Hartleys.Its interim analysis, expected between late 2025 and early 2026, will determine whether its drug candidate demonstrates efficacy at this point in the trial. It will only proceed if the US Food and Drug Administration  agrees to the interim analysis, the firm is satisfied with the FDA's terms, a powering analysis supports it, and the trial is fully recruited.A blinded statistical power analysis, expected in the December quarter, will verify if Dimerix's trial has adequate statistical power for the confirmatory endpoint, confirming enough patients have been enrolled to detect a meaningful effect at study completion.The investment firm maintained its speculative buy recommendation on Dimerix and its AU$1.68 per share price target.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","FSGS","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2575416222","title":"3 hot sectors, a handful of stock ideas, and what could come next","url":"https://stock-news.laohu8.com/highlight/detail?id=2575416222","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575416222?lang=en_us&edition=fundamental","pubTime":"2025-10-15 04:00","pubTimestamp":1760472030,"startTime":"0","endTime":"0","summary":"There have been three dominant sector winners in the last 12 months – AI, gold and defence. These should hardly come as a surprise.There are queues down Martin Place to purchase bullion. Geopolitical risks have heightened and, on the back of a US push, most economies are stepping up their defence spending. And AI hardly needs an explanation as it continues its game-changing growth.Conversely, it’s been a hard year for healthcare, which has been hit by the US tariff on pharmaceuticals, along with vaccine scepticism, and pricing pressures.There’s also been plenty of good economic news out of the US to bolster markets – inflation appears steady, jobs numbers have held up for the most part, and the rate-cutting cycle is still underway to support consumer spending. The story has been mostly similar in Australia – even with a surprise jump in the last inflation print.Only last week, the S&P500 reached 6,764.66 while the S&P/ASX 200 hit an all-time high of 9054.50 back in August. It wasn’t th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/3-hot-sectors-a-handful-of-stock-ideas-and-what-could-come-next","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/3-hot-sectors-a-handful-of-stock-ideas-and-what-could-come-next","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4543","UNI.AU","XKO.AU","BK4539","FIX","BK7501","APE.AU","SKS.AU","DXB.AU","BK7016","BK4167","BK7067","BK7506","LU2087625088.SGD","BK7115","XAO.AU","IE00B894F039.SGD","BK4608","BK7094","DRO.AU","BK7023","BK4185","CRWV","DUG.AU","IE00B19Z9Z06.USD","LU0097036916.USD","MLX.AU","AI","BK7057","NUTX","BK7143","TUA.AU","LU0353189680.USD","LRV.AU","AMI.AU","BK4023","SXE.AU","IE00BZ9MQY76.HKD","PPE.AU","APP","BK4196","XJO.AU","BK4551","IE00B19Z9P08.USD","BBN.AU","BK4588","AYA.AU","EOL.AU","BK7021","BK4129"],"gpt_icon":1},{"id":"2573151719","title":"Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573151719","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573151719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 10:48","pubTimestamp":1759891712,"startTime":"0","endTime":"0","summary":"Dimerix  said the results of an analysis by Parasol are consistent with the analysis conducted last year that supported the use of proteinuria as a clinical trial endpoint for focal segmental glomerulosclerosis, a kidney disease, according to a Wednesday filing with the Australian bourse.The company said the results cannot be disclosed as they are subject to commercial-in-confidence restrictions.The company, along with its US partner Amicus Therapeutics, intends to seek feedback from the US Food and Drug Administration on the new findings in the coming months, the filing said.Shares of the company rose 7% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}